Cihan Ay

Cihan Ay's AcademicInfluence.com Rankings

Cihan Ay

Computer Science

#9904

World Rank

#10390

Historical Rank

Computer Engineering

#141

World Rank

#143

Historical Rank

Data Science

#251

World Rank

#256

Historical Rank

Computational Linguistics

#2457

World Rank

#2481

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Cihan Ay Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cihan Ay's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prediction of venous thromboembolism in cancer patients. (2010) (661)
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). (2007) (385)
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2009) (363)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2019) (359)
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis (2020) (294)
High D-dimer levels are associated with poor prognosis in cancer patients (2012) (279)
Cancer-associated venous thromboembolism: Burden, mechanisms, and management (2016) (270)
Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients (2012) (239)
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021) (236)
High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (213)
Biomarkers for prediction of venous thromboembolism in cancer. (2013) (212)
Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. (2011) (205)
Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. (2015) (194)
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. (2018) (179)
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (176)
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer (2013) (176)
Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients (2018) (160)
Venous thromboembolism in cancer patients: a population-based cohort study. (2020) (151)
Biomarkers and Venous Thromboembolism (2009) (145)
Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. (2017) (140)
High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study (2009) (136)
High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. (2007) (124)
Venous thromboembolism--a manifestation of the metabolic syndrome. (2007) (120)
Management of cancer‐associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH (2018) (119)
Venous thrombosis and cancer: from mouse models to clinical trials (2015) (114)
Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2012) (106)
Thrombin generation in morbid obesity: significant reduction after weight loss (2010) (99)
Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors (2019) (94)
Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) (2021) (91)
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH (2019) (90)
Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting (2016) (89)
Platelets in cancer and thrombosis (2014) (87)
Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. (2020) (86)
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer (2018) (82)
Circulating procoagulant microparticles in cancer patients (2011) (79)
Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality (2014) (73)
Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). (2014) (70)
Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease (2017) (70)
Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation (2016) (70)
The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera (2009) (70)
Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants (2016) (69)
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants (2019) (67)
Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. (2014) (66)
Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality (2015) (65)
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study (2013) (65)
Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features (2013) (64)
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity (2018) (64)
Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials (2012) (64)
Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) (2015) (63)
Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer (2019) (61)
Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). (2015) (60)
Hypercoagulabilty, venous thromboembolism, and death in patients with cancer (2016) (59)
Low‐density lipoprotein receptor‐related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism (2007) (58)
Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. (2019) (58)
Circulating procoagulant microparticles in patients with venous thromboembolism. (2009) (57)
Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size (2017) (56)
Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. (2013) (55)
Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis (2017) (54)
Thrombosis risk and survival in cancer patients with elevated C‐reactive protein (2011) (53)
Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI) (2017) (53)
Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study (2018) (51)
Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. (2016) (51)
Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. (2014) (50)
Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH (2017) (50)
Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials (2020) (49)
Anticoagulation of cancer patients with non‐valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH (2019) (49)
Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment (2016) (49)
Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. (2011) (49)
The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs (2008) (49)
Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review (2018) (46)
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism (2018) (41)
Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism: Results of a Patient-Level Meta-Analysis (2014) (40)
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran (2017) (40)
Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis (2015) (40)
Tests predictive of thrombosis in cancer. (2010) (40)
Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges (2019) (39)
Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life (2022) (39)
Association of platelet activation markers with cancer-associated venous thromboembolism (2016) (38)
Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. (2012) (38)
Clinical significance of circulating microparticles for venous thrombo - embolism in cancer patients (2012) (37)
Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis (2016) (36)
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. (2021) (36)
Venous Thromboembolism - A Manifestation of the Metabolic Syndrome?. (2006) (36)
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art (2015) (36)
Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women (2010) (36)
High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB) (2018) (35)
The role of podoplanin in cancer-associated thrombosis. (2018) (35)
Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. (2017) (35)
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 (2022) (34)
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban (2015) (34)
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement (2019) (34)
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS) (2015) (34)
Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients (2014) (33)
P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism (2008) (33)
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options (2017) (32)
Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer (2018) (32)
IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017) (32)
Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function (2018) (31)
The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study (2019) (30)
Alterations of blood coagulation in controlled human malaria infection (2016) (30)
The role of fibrinogen plasma levels, the –455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis (2011) (27)
Surgical treatment of the haemophilic pseudotumour: A single centre experience (2012) (26)
Outcome of total knee arthroplasty in hemophilic arthropathy. (2014) (26)
How I treat cancer-associated thrombosis (2020) (26)
Clinical implications of incidental venous thromboembolism in cancer patients (2019) (26)
Epidemiology and risk factors for venous thromboembolism in lung cancer (2016) (25)
Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. (2014) (25)
Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. (2014) (25)
Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. (2014) (24)
Risk of venous thromboembolism and primary prophylaxis in cancer (2012) (24)
Oral anticoagulation with rivaroxaban during pregnancy: a case report (2014) (24)
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study (2020) (24)
Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer (2019) (23)
Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. (2018) (23)
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease (2012) (23)
Hemoglobin, alkalic phosphatase, and C‐reactive protein predict the outcome in patients with liposarcoma (2015) (23)
Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism (2013) (22)
The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. (2018) (22)
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. (2020) (22)
Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) (21)
Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation (2018) (21)
Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study (2015) (20)
Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. (2014) (20)
Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. (2016) (20)
Elevated serum creatinine and low albumin are associated with poor outcomes in patients with liposarcoma (2016) (20)
Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital (2020) (19)
The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism (2007) (19)
The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism (2012) (19)
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease (2014) (19)
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. (2021) (18)
Platelet activation and function during eltrombopag treatment in immune thrombocytopenia (2011) (18)
Long-term survival of patients with a history of venous thromboembolism (2010) (18)
Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (18)
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. (2020) (18)
Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry (2016) (17)
Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. (2022) (17)
Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery (2016) (17)
Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer (2020) (17)
Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease (2019) (17)
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. (2020) (17)
Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause (2019) (16)
Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis. (2020) (16)
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients (2015) (16)
Procoagulant extracellular vesicles in amniotic fluid (2017) (16)
Serum creatinine and albumin predict sarcoma‐specific survival in patients with myofibroblastic and fibroblastic sarcomas (2017) (16)
Thrombin generation in patients with a bleeding tendency of unknown origin (2011) (16)
Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation (2019) (15)
Successful outcome in a pregnant woman with homozygous antithrombin deficiency (2007) (15)
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. (2021) (15)
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study (2021) (15)
The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review (2020) (15)
Establishing an online physical exercise program for people with hemophilia (2019) (15)
Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention (2018) (15)
The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease (2020) (15)
Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism (2020) (14)
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study (2018) (14)
Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. (2020) (14)
VTE risk assessment in cancer (2016) (13)
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability (2016) (13)
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score (2021) (13)
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence (2022) (13)
Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. (2020) (13)
Myeloid but not epithelial tissue factor exerts protective anti‐inflammatory effects in acid aspiration‐induced acute lung injury (2017) (13)
Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis (2020) (13)
Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation (2021) (13)
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting (2020) (12)
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts (2020) (12)
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. (2019) (12)
Pain management in hemophilia: expert recommendations (2021) (12)
Platelets and hemophilia: A review of the literature. (2017) (12)
The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. (2020) (12)
Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review (2021) (11)
Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation—Results of a randomized controlled crossover study (2016) (11)
PO-63 - Exhausted platelets in cancer patients with high risk of venous thromboembolism and poor prognosis. (2016) (11)
Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry (2022) (11)
Treatment and secondary prevention of venous thromboembolism in cancer patients (2012) (11)
Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. (2017) (11)
Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma (2019) (11)
Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability (2021) (10)
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI). (2017) (10)
Factor XI‐deficient mice exhibit increased bleeding after injury to the saphenous vein (2017) (10)
Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study (2020) (9)
Comparison of metal on metal versus polyethylene–ceramic bearing in uncemented total hip arthroplasty in patients with haemophilic arthropathy (2014) (9)
Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause (2015) (9)
Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia - A case-based review of clinical management. (2021) (9)
A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS (2007) (9)
OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients? (2016) (8)
Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism (2020) (8)
Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A (2020) (8)
Response to antiplatelet therapy is independent of endogenous thrombin generation potential. (2013) (8)
Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting (2018) (8)
Tissue Factor: Catch Me If You Can! (2017) (8)
Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. (2020) (8)
Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer (2021) (8)
Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals (2020) (8)
Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Polymorphism 663 C>T Affects Clotting Factor VIII Activity and Increases the Risk of Venous Thromboembolism. (2006) (7)
Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivors—A Prospective Observational Study (2019) (7)
How I Manage Cancer-Associated Thrombosis (2020) (7)
Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives (2021) (7)
Function of platelets in apheresis platelet concentrates and in patient blood after transfusion as assessed by Impact‐R (2009) (7)
Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. (2021) (7)
Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future (2020) (7)
Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis (2018) (6)
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population‐based prospective cohort study (2021) (6)
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma (2020) (5)
Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. (2012) (5)
The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. (2011) (5)
Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation. (2022) (5)
Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. (2020) (5)
Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. (2010) (5)
High Levels of Soluble P-Selectin Are Associated with the Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. (2006) (5)
Influence of Imprinting of an X Chromosome and of the MethyleneTetrahydrofolate Reductase (MTHFR) 677C>T Polymorphism on FVIII Activity (2015) (5)
Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy (2014) (5)
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel (2021) (5)
Risk assessment for recurrent venous thromboembolism in patients with cancer (2021) (5)
Risk assessment models of cancer-associated thrombosis - Potentials and perspectives (2021) (5)
Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. (2021) (5)
Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. (2019) (4)
Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism? (2017) (4)
Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS) (2008) (4)
Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. (2020) (4)
ABO blood group type and risk of venous thromboembolism in patients with cancer (2022) (4)
Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review (2018) (4)
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism. (2022) (4)
Unanswered questions in cancer‐associated thrombosis (2022) (4)
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing (2022) (4)
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. (2020) (4)
Longitudinal analysis of extracellular vesicle-associated tissue factor activity in cancer patients. (2020) (4)
Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites (2021) (3)
Bleeding Risk Assessment in Patients with Venous Thromboembolism (2021) (3)
Characterisation of inflammatory response, coagulation, and radiological findings in Katayama fever: a report of three cases at the Medical University of Vienna, Austria (2014) (3)
Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices (2021) (3)
Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer (2022) (3)
Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. (2022) (3)
Risk of venous thromboembolism and primary prophylaxis in cancer (2012) (3)
Correction: Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease (2018) (3)
[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. (2018) (3)
Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria (2021) (3)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Wien, 28. September - 2. Oktober 2018: Abstracts (2018) (2)
Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII (2022) (2)
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline†. (2023) (2)
First application of focused low-energy extracorporeal shockwave therapy in a patient with severe hemophilia A and plantar fasciitis (2020) (2)
MEDICAL RADIATION THERAPIES (2013) (2)
SP478PREVALENCE OF ATRIAL FIBRILLATION AND PRACTICE PATTERNS OF ANTITHROMBOTIC THERAPY IN A POPULATION-BASED COHORT STUDY OF HEMODIALYSIS PATIENTS: THE VIENNA INVESTIGATION OF ATRIAL FIBRILLATION AND THROMBOEMBOLISM IN HEMODIALYSIS PATIENTS (VIVALDI) (2016) (2)
Disseminated Intravascular Coagulation Score Predicts Mortality in Patients with Liver Disease and Low Fibrinogen Level (2022) (2)
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors (2021) (2)
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. (2020) (2)
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease (2022) (2)
PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. (2016) (2)
Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS) (2015) (2)
Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need (2022) (2)
The role of scientific publishing in the development of early career investigators (2017) (2)
Interleukin‐4 receptor alpha signaling regulates monocyte homeostasis (2022) (2)
Development and validation of a clinical prediction model for cancer-associated venous thromboembolism in two independent prospective cohorts (2020) (1)
Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier (2018) (1)
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors (2022) (1)
Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism (2021) (1)
VTE risk assessment in cancer (2016) (1)
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study (2018) (1)
Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS). (2012) (1)
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia (2021) (1)
Comment on Ferroni et al.: “Impact of chemotherapy on venous thromboembolism. (2014) (1)
Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin (2011) (1)
Management of pulmonary embolism in patients with cancer (2018) (1)
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group (2022) (1)
von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. (2022) (1)
Medical and Neuro-Oncology (2010) (1)
Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day (2022) (1)
Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism (2019) (1)
The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease (2019) (1)
OC-13 A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts (2021) (1)
Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach. (2022) (1)
The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis (2018) (1)
Platelets in cancer and thrombosis (2014) (1)
The post-VTE functional status scale for assessment of functional limitations in patients with venous thromboembolism: Construct validity and responsiveness in a prospective cohort study. (2022) (1)
The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector‐based COVID‐19 vaccination: Where there is much light, the shadow is deep (2021) (1)
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. (2023) (1)
Association of systemic inflammation with local tumour characteristics and survival in glioma patients (2019) (1)
Fibrinolysis and bleeding of unknown cause (2021) (1)
Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study (2022) (1)
Risk Factors in Cancer Patients (2021) (1)
Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model (2021) (1)
Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia. (2023) (0)
Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) (0)
Annexin A5 Resistance Is Associated with Thrombotic Risk in Patients with the Lupus Anticoagulant: The Vienna Lupus Anticoagulant and Thrombosis Study (LATS) (2015) (0)
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. (2022) (0)
Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status (2023) (0)
P5376Interleukin-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017) (0)
P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA (2022) (0)
Coagulation signaling from amniotic fluid to fetal skin (2022) (0)
556PINTEGRIN BETA-3 GENETIC VARIANTS PREDICT THE RISK OF THROMBO-EMBOLIC EVENTS IN PATIENTS WITH COLORECTAL CANCER. (2014) (0)
Primäre Thromboseprophylaxe bei Krebspatienten (2012) (0)
Treatment and secondary prevention of venous thrombo -embolism in cancer patients (2012) (0)
Correlation of systemic and local inflammation with survival prognosis in glioma patients. (2019) (0)
Correction: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [Thrombosis Journal, 16, (2018) (9)] DOI: 10.1186/s12959-018-0163-7 (2018) (0)
The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS (2010) (0)
Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation (2021) (0)
Impaired hemostatic capacity in patients with low von Willebrand factor (2023) (0)
Primäre Thromboseprophylaxe bei Krebspatienten (2021) (0)
Circulatory microRNAs as potential biomarkers for major adverse cardiac events in patients with atrial fibrillation (2021) (0)
Risk stratification and prevention of venous thromboembolic disease in cancerology (2014) (0)
Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia (2021) (0)
[Tumor and thrombosis]. (2012) (0)
Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness Biomarkers and Venous Thromboembolism (2009) (0)
Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank (2023) (0)
PO-89 Performance of the ‘4S rule' to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism (2021) (0)
Neutrophil-to-Lymphocyte Ratio and the Risk of Venous Thromboembolism and Mortality in Patients with Cancer (2018) (0)
Thrombomodulin in patients with mild to moderate bleeding tendency (2021) (0)
Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer (2020) (0)
Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting (2023) (0)
Von Willebrand factor antigen is linked to bacterial translocation, inflammation, as well as procoagulant imbalance and predicts complications of cirrhosis independently of portal hypertension severity (2017) (0)
Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis (2019) (0)
The influence of cancer on platelet behaviour Thrombocytosis in cancer (2017) (0)
Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients (2023) (0)
Epidemiology, risk profile, management, and outcome in geriatric patients with atrial fibrillation in two long-term care hospitals (2022) (0)
Age-related changes of neutrophil characteristics, potential of activation, DNA release and NET formation (2020) (0)
Venous Thromboembolism — A Metabolic Disease? (2008) (0)
Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study (2023) (0)
Association between index venous thromboembolism (VTE) event and 12-months outcomes for patients in routine clinical practice enrolledin the Edoxaban Treatment in routine cliNical prActice for patients with acute VTE in Europe (ETNA-VTE-Europe) registry (2020) (0)
PS1582 DECREASED PLATELET REACTIVITY IS ASSOCIATED WITH AN INFLAMMATORY STATUS IN PATIENTS WITH CANCER (2019) (0)
P6227Prognostic impact of soluble p-selectin on long-term adverse cardiovascular outcome in patients with acute and stable coronary artery disease (2017) (0)
Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study (2022) (0)
Highly Procoagulant Extracellular Vesicles in Amniotic Fluid (2016) (0)
Extracellular vesicle-associated tissue factor activity is increased in prostate cancer patients with disseminated intravascular coagulation and induced by cellular interactions in vitro (2018) (0)
TEMPORARY REMOVAL: PO-01: KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study. (2022) (0)
Chronic pulmonary hypertension 47 P327 | BEDSIDE The right to left atrial and ventricular area ratio, left ventricular area,TAPSE and right ventricular global strain can predict three-year survival in patients with pulmonary hypertension (0)
PO-67 Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired versus outpatient) at diagnosis in the era of incidental events (2021) (0)
Association of telomere length and mitochondrial DNA copy number, two biomarkers of biological aging, with the risk of venous thromboembolism. (2023) (0)
Blood group non-O is not associated with long-term adverse outcomes in patients undergoing percutaneous coronary intervention (2023) (0)
Association of Elevated Soluble P-Selectin Levels and Fetal Loss in Women with a History of Venous Thromboembolism. (2008) (0)
Integrin genetic variants and risk of thromboembolic events in patients with colorectal cancer. (2014) (0)
PO-36 A high platelet count independently predicts venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2007) (0)
Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer (2023) (0)
Improvements in short- and long-term outcomes in patients with pulmonary embolism after outpatient pulmonary rehabilitation (2020) (0)
Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII (2023) (0)
Praktische Aspekte im Einsatz von Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier // Practical considerations on the use of edoxaban (2018) (0)
Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm (2021) (0)
The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors (2018) (0)
Intraperitoneal Activation of Blood Coagulation via Tissue Factor Exposing Extracellular Vesicles in Patients with Liver Disease and Ascites (2019) (0)
Late Breaking Abstract - Outpatient pulmonary rehabilitation in patients with long COVID (2021) (0)
Myeloid but not epithelial tissue factor exerts protective anti-inflammatory properties in acid aspiration-induced acute lung injury. (2017) (0)
37. Jahrestagung der Österreichischen Diabetes Gesellschaft (2009) (0)
P1669: AUTOANTIBODY-MEDIATED PLATELET DESIALYLATION IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (2022) (0)
Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia (2019) (0)
Peri-Interventional Triple Therapy with Dabigatran Modifies Vasomotion after Bare-Metal Stent Implantation in a Pig Coronary Artery Model (2023) (0)
Das Österreichische Hämophilie-Register (2020) (0)
How I Manage Cancer-Associated Thrombosis Management der Krebs-assoziierten Thrombose (2020) (0)
Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A (2023) (0)
Altered Protein Profiles in Platelets of Lupus Anticoagulant Positive Patients - New Players in LA-related Thrombosis? (2019) (0)
High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients. (2009) (0)
Heparins as cancer therapy: in theory, they should have worked. (2020) (0)
Tissue Factor-Related Biomarkers and Prediction of Cancer-Associated VTE: Correlative Analyses of the Phacs Trial (2017) (0)
Differences in the platelet proteome between patients with cancer at high risk of venous thromboembolism and healthy controls (2018) (0)
P1665: WHOLE-BLOOD ROTATIONAL THROMBOELASTOMETRY (ROTEM) AS A DIAGNOSTIC TOOL IN PATIENTS WITH BLEEDING OF UNKNOWN CAUSE (BUC) (2022) (0)
Anticoagulation in Patients with Brain Metastases (2019) (0)
[Title: Covid-19-associated coagulopathy]. (2021) (0)
1552P Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX (2020) (0)
PO-32 Prediction of venous thromboembolism in cancer patients by measuring thrombin generation – Results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (0)
Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis (2020) (0)
TEMPORARY REMOVAL: PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer. (2022) (0)
P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer (2019) (0)
Growth differentiation factor-15 (GDF-15) predicts major bleeding, major adverse cardiac events, and mortality in patients with end-stage kidney disease on hemodialysis: findings from the VIVALDI study. (2022) (0)
Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a (2019) (0)
1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors (2020) (0)
Delayed Plasma Clot Lysis in Adult Patients with Primary Immune Thrombocytopenia (ITP) (2021) (0)
Krafttraining bei Patienten mit Hämophilie – eine Übersichtsarbeit (2018) (0)
Primäre Thromboseprophylaxe bei Krebspatienten (2020) (0)
Plasma levels of soluble P-selectin predict survival in CTEPH (2013) (0)
Characterization of a prothrombotic phenotype using thrombin generation and thrombin activity in cirrhosis and portal hypertension. (2023) (0)
SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease (2019) (0)
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer (2022) (0)
Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency (2021) (0)
P-selectin ready for the News at Six (2009) (0)
Alterations of blood coagulation in controlled human malaria infection (2016) (0)
THROMBOSIS AND HEMOSTASIS Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism (2017) (0)
Primäre Thromboseprophylaxe bei Krebspatienten (2012) (0)
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies (2022) (0)
Programmed Cell Death Ligand 1 and Venous Thromboembolism in Patients with Primary Brain Tumors (2019) (0)
Neutrophils in lung cancer patients: Activation potential and neutrophil extracellular trap formation. (2023) (0)
PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study (2021) (0)
Accelerated endoplasmic reticulum and coagulation factor processing in platelets are linked with the hypercoagulable state of patients with lung cancer (2021) (0)
D-dimer levels and prediction of overall survival in cancer patients. (2010) (0)
Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation (2023) (0)
Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer (2022) (0)
Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer (2021) (0)
Risk factors for future bleeding in patients with mild bleeding disorders: longitudinal data from the Vienna Bleeding Biobank. (2023) (0)
Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function (2017) (0)
Role of neutrophils and neutrophil extracellular traps in mice bearing human pancreatic tumors (2019) (0)
SP538SOLUBLE P-SELECTIN PREDICTS CARDIOVASCULAR EVENTS IN END STAGE RENAL DISEASE (2015) (0)
Repeated Testing Unfolds the Challenge of Diagnosing Von Willebrand Disease: Longitudinal Data from the Vienna Bleeding Biobank (2022) (0)
Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant (2021) (0)
38. Jahrestagung der Österreichischen Diabetes Gesellschaft. "Translation of Science – von der Forschung in die Praxis", Gastherausgeber: Präsident: Univ.-Doz. Dr. Raimund Weitgasser, Erster Sekretär: Univ.-Doz. Dr. Bernhard Paulweber, Salzburg, 18.–20. November 2010 (2010) (0)
COVID-19-assoziierte Koagulopathie (2021) (0)
Das Göttinger Grid-Ressourcen-Zentrum GoeGrid (2009) (0)
OC-11 Plasminogen activator inhibitor 1 enhances venous thrombosis in pancreatic cancer (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cihan Ay?

Cihan Ay is affiliated with the following schools:

Medical University of Vienna
First Moscow State Medical University
University of North Carolina at Chapel Hill

Cihan Ay's Academic­Influence.com Rankings

Why Is Cihan Ay Influential?

Cihan Ay's Published Works

Published Works

What Schools Are Affiliated With Cihan Ay?

Cihan Ay's AcademicInfluence.com Rankings